China lists high-value consumables for national management



China’s National Healthcare Commission (NHC) released notification of a first batch of high-value medical consumables that will be added to the national key management list​. See the table below for full details.

According to the notice, all local medical and healthcare bureaus are required to add varieties to the national list and draw up local lists, and guide medical institutions to come up with their own lists under their own jurisdictions.

The State Council released a "High-value medical consumables administration reform plan" on July 30 last year, as GBI reported. The plan proposes to strengthen the standardized management of high-value medical consumables, clarify the scope of governance, and focus on managing high-value medical consumables with relatively high unit prices.


First national key management list high-for value medical consumables

No.

Product name

1

Single / multi-component metal bone fixation instruments and accessories

2

Guide wire

3

In-ear prosthetics

4

Materials and products for maxillofacial restoration and reconstruction

5

Spinal interbody fixation / replacement systems

6

Absorbable surgical hemostatic materials

7

Hip prosthetics

8

Skull orthopedic instruments

9

Bone planers

10

Balloon dilatation catheters

11

Brackets

12

Stapler (with staples)

13

Stents

14

Penile prosthetics

15

Implantable neurostimulators

16

Implantable cardioverter defibrillators

17

Implantable drug infusion devices

18

Vertebroplasty guidance systems


Reference:

Related news
GBI analysis shows that Takeda subsidiary Shire’s Adynovate (rurioctocog alfa pegol) this week obtained market clearance from Brazil’s National Health Surveillance Agency (ANVISA).
Germany-based Bayer this week obtained marketing approval from Brazil’s National Health Surveillance Agency (ANVISA) for its hemophilia treatment Kovaltry (octocog beta), according to GBI analysis.
The Health Commission of Henan Province (HNHC) released a notification cranking up management at medical institutions across the province, focused on 50 high-value medical consumables that have been blacklisted from the pharmaceutical procurement platform. The devices involve areas including vascular intervention, orthopedics, electrophysiology, neurosurgery, extracorporeal circulation and blood purification.
CSL Behring, a wholly owned subsidiary of Australia-based CSL Ltd, this week received registration approval from Brazil’s National Health Surveillance Agency (ANVISA) for its antihemorrhagic Afstyla (lonoctocog alfa), according to GBI analysis.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd’s (603707.SSE) Abbreviated New Drug Application (ANDA) for enoxaparin sodium injection USP has been approved by the US FDA.
Recent news
China’s Center for Drug Evaluation (CDE) published the 27th chemical generic reference preparations list, soliciting public feedback from January 20 to February 5.
China’s Sino Biopharmaceutical Ltd (HKEX.01177) announced that subsidiary Nanjing Chia Tai Weikang Biopharmaceutical Co., Ltd (GBI translation) has entered into a marketing agreement with Switzerland-based Octapharma AG.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) subsidiary Shanghai Henlius Pharmaceutical Co., Ltd (HKG.02696) announced clinical approval from the National Medical Products Administration (NMPA) in relation to its recombinant anti-HER2 domain II monoclonal antibody (mAb) HLX11, a biosimilar of Swiss giant Roche’s Perjeta (pertuzumab).
  • 1579664967786
  • China
  • Drug
Beigene Ltd released a press release announcing its successful bid for Abraxane paclitaxel (nanoparticle ablumin-bound) during the recently completed second round of the volume-based procurement (VBP) program.
US major Eli Lilly’s type 2 diabetes drug candidate tirzepatide (LY3298176) has obtained 6 tacit clinical trial approvals from the Center for Drug Evaluation (CDE), according to the bureau’s website.
China-based biotech BeiGene Ltd (Nasdaq.BGNE) announced that a Phase III clinical study for the programmed death-1 (PD-1) antibody tislelizumab in combination with two chemotherapies reached primary endpoint in a Phase III study as a first-line treatment for squamous non-small cell lung cancer (sqNSCLC).
  • 1579661419502
  • China
  • Drug
Hangzhou-based Gmax Biopharm LLC picked up a tacit clinical trial approval for GMA301, a Class 1 recombinant anti-human endothelin receptor A monoclonal antibody (mAb).
Analytics Snapshot


Analytics Snapshot